222 related articles for article (PubMed ID: 31076164)
1. Movement Disorders and Voice.
Snow G; Guardiani E
Otolaryngol Clin North Am; 2019 Aug; 52(4):759-767. PubMed ID: 31076164
[TBL] [Abstract][Full Text] [Related]
2. Refractory Dysphonia Due to Isolated Cricothyroid Muscle Dystonia.
Kraft S; Childes J; Hillel A; Schindler J
J Voice; 2016 Jul; 30(4):501-5. PubMed ID: 26239970
[TBL] [Abstract][Full Text] [Related]
3. Differences in botulinum toxin dosing between patients with adductor spasmodic dysphonia and essential voice tremor.
Orbelo DM; Duffy JR; Hughes Borst BJ; Ekbom D; Maragos NE
J Voice; 2014 Jan; 28(1):123-7. PubMed ID: 24080335
[TBL] [Abstract][Full Text] [Related]
4. Laryngeal electromyography in movement disorders: preliminary data.
Kimaid PA; Quagliato EM; Crespo AN; Wolf A; Viana MA; Resende LA
Arq Neuropsiquiatr; 2004 Sep; 62(3A):741-4. PubMed ID: 15334243
[TBL] [Abstract][Full Text] [Related]
5. Vocal Parameters and Self-Perception in Individuals With Adductor Spasmodic Dysphonia.
Rojas GVE; Ricz H; Tumas V; Rodrigues GR; Toscano P; Aguiar-Ricz L
J Voice; 2017 May; 31(3):391.e7-391.e18. PubMed ID: 27866691
[TBL] [Abstract][Full Text] [Related]
6. Combined-modality treatment of adductor spasmodic dysphonia with botulinum toxin and voice therapy.
Murry T; Woodson GE
J Voice; 1995 Dec; 9(4):460-5. PubMed ID: 8574315
[TBL] [Abstract][Full Text] [Related]
7. Indirect laryngoscopic approach for injection of botulinum toxin in spasmodic dysphonia.
Ford CN; Bless DM; Lowery JD
Otolaryngol Head Neck Surg; 1990 Nov; 103(5 ( Pt 1)):752-8. PubMed ID: 2126097
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of spasmodic dysphonia with botulinum toxin].
Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
[TBL] [Abstract][Full Text] [Related]
9. Spasmodic Dysphonia: A Review. Part 1: Pathogenic Factors.
Hintze JM; Ludlow CL; Bansberg SF; Adler CH; Lott DG
Otolaryngol Head Neck Surg; 2017 Oct; 157(4):551-557. PubMed ID: 28850801
[TBL] [Abstract][Full Text] [Related]
10. Spasmodic Dysphonia.
Lin J; Sadoughi B
Adv Otorhinolaryngol; 2020; 85():133-143. PubMed ID: 33166970
[TBL] [Abstract][Full Text] [Related]
11. Considerations for initial dosing of botulinum toxin in treatment of adductor spasmodic dysphonia.
Rosow DE; Parikh P; Vivero RJ; Casiano RR; Lundy DS
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):1003-6. PubMed ID: 23535709
[TBL] [Abstract][Full Text] [Related]
12. Clinical Practice Guideline: Hoarseness (Dysphonia) (Update).
Stachler RJ; Francis DO; Schwartz SR; Damask CC; Digoy GP; Krouse HJ; McCoy SJ; Ouellette DR; Patel RR; Reavis CCW; Smith LJ; Smith M; Strode SW; Woo P; Nnacheta LC
Otolaryngol Head Neck Surg; 2018 Mar; 158(1_suppl):S1-S42. PubMed ID: 29494321
[TBL] [Abstract][Full Text] [Related]
13. Clinical practice guideline: hoarseness (dysphonia).
Schwartz SR; Cohen SM; Dailey SH; Rosenfeld RM; Deutsch ES; Gillespie MB; Granieri E; Hapner ER; Kimball CE; Krouse HJ; McMurray JS; Medina S; O'Brien K; Ouellette DR; Messinger-Rapport BJ; Stachler RJ; Strode S; Thompson DM; Stemple JC; Willging JP; Cowley T; McCoy S; Bernad PG; Patel MM
Otolaryngol Head Neck Surg; 2009 Sep; 141(3 Suppl 2):S1-S31. PubMed ID: 19729111
[TBL] [Abstract][Full Text] [Related]
14. Long-term effects of botulinum toxin injections in spasmodic dysphonia.
Davidson BJ; Ludlow CL
Ann Otol Rhinol Laryngol; 1996 Jan; 105(1):33-42. PubMed ID: 8546422
[TBL] [Abstract][Full Text] [Related]
15. [Indications for botulinum toxin in laryngectomy].
Klap P; Marion MH; Perrin A; Fresnel-Elbaz E; Cohen M
Rev Laryngol Otol Rhinol (Bord); 1993; 114(4):281-7. PubMed ID: 8029549
[TBL] [Abstract][Full Text] [Related]
16. Adductor spasmodic dysphonia: case reports with acoustic analysis following botulinum toxin injection and acupuncture.
Crevier-Buchman L; Laccourreye O; Papon JF; Nurit D; Brasnu D
J Voice; 1997 Jun; 11(2):232-7. PubMed ID: 9181547
[TBL] [Abstract][Full Text] [Related]
17. [Botulinum toxin. A new therapeutic alternative in spastic dysphonia (laryngeal abductor dystonia)].
Loven JO; Brøndbo K; Ganes T
Tidsskr Nor Laegeforen; 1993 Mar; 113(7):841-3. PubMed ID: 8480289
[TBL] [Abstract][Full Text] [Related]
18. Quality of Life After Botulinum Toxin Injection in Patients With Adductor Spasmodic Dysphonia; a Systematic Review and Meta-analysis.
Faham M; Ahmadi A; Silverman E; Harouni GG; Dabirmoghaddam P
J Voice; 2021 Mar; 35(2):271-283. PubMed ID: 31477348
[TBL] [Abstract][Full Text] [Related]
19. Quantitative laryngeal electromyography parameters may correlate with improved outcomes following botulinum toxin injection for spasmodic dysphonia.
Dwyer CD; Leclerc AA; Nandedkar SD; Young VN; Rosen CA
Muscle Nerve; 2021 Apr; 63(4):525-530. PubMed ID: 33382480
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing botulinum toxin dose instability in spasmodic dysphonia patients.
Rosow DE; Pechman A; Saint-Victor S; Lo K; Lundy DS; Casiano RR
J Voice; 2015 May; 29(3):352-5. PubMed ID: 25242042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
